Literature DB >> 15036400

Age associated changes of AGE-receptor expression: RAGE upregulation is associated with human heart dysfunction.

A Simm1, C Casselmann, A Schubert, S Hofmann, A Reimann, R-E Silber.   

Abstract

The binding of advanced glycation endproducts (AGEs) to their receptors is known to cause changes in cell function during normal ageing and is implicated in the pathogenesis of cardiovascular disease. In this study, expression of the AGE-receptor 3 (AGE-R3) and the receptor for AGEs (RAGE) was compared on the mRNA and protein level in the ageing human heart. Western blot and RT-PCR analysis of the AGE receptors from the cardiac auricles in senescent and adult patients was performed and compared with young controls. Whereas the expressions of AGE-R3 as well as RAGE protein were significantly upregulated in the senescent population, only the upregulation of RAGE is associated with reduced heart function. Therefore, our results support a pathophysiological function for RAGE in the ageing human heart.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15036400     DOI: 10.1016/j.exger.2003.12.006

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  21 in total

1.  Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex.

Authors:  Nicola Origlia; Camilla Bonadonna; Alfredo Rosellini; Elena Leznik; Ottavio Arancio; Shirley Shidu Yan; Luciano Domenici
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

Review 2.  Does accumulation of advanced glycation end products contribute to the aging phenotype?

Authors:  Richard D Semba; Emily J Nicklett; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-17       Impact factor: 6.053

Review 3.  Views from within and beyond: narratives of cardiac contractile dysfunction under senescence.

Authors:  Xiaoping Yang; Nair Sreejayan; Jun Ren
Journal:  Endocrine       Date:  2005-03       Impact factor: 3.633

4.  Is there any association between GLY82 ser polymorphism of rage gene and Turkish diabetic and non diabetic patients with coronary artery disease?

Authors:  Ozlem Kucukhuseyin; Hulya Yilmaz-Aydogan; C Selim Isbir; Turgay Isbir
Journal:  Mol Biol Rep       Date:  2011-09-25       Impact factor: 2.316

5.  Association between the receptor for advanced glycation end products gene polymorphisms and coronary artery disease.

Authors:  Lan Liu; Xing-biao Qiu
Journal:  Mol Biol Rep       Date:  2013-11       Impact factor: 2.316

Review 6.  Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure.

Authors:  Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Curr Heart Fail Rep       Date:  2012-06

7.  Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors.

Authors:  Michela Guglielmotto; Luca Giliberto; Elena Tamagno; Massimo Tabaton
Journal:  Front Aging Neurosci       Date:  2010-02-09       Impact factor: 5.750

8.  RAGE inhibition in microglia prevents ischemia-dependent synaptic dysfunction in an amyloid-enriched environment.

Authors:  Nicola Origlia; Chiara Criscuolo; Ottavio Arancio; Shirley ShiDu Yan; Luciano Domenici
Journal:  J Neurosci       Date:  2014-06-25       Impact factor: 6.167

9.  Aging is associated with greater nuclear NF kappa B, reduced I kappa B alpha, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans.

Authors:  Anthony J Donato; Alexander D Black; Kristen L Jablonski; Lindsey B Gano; Douglas R Seals
Journal:  Aging Cell       Date:  2008-09-08       Impact factor: 9.304

10.  Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs.

Authors:  Christos Tikellis; Merlin C Thomas; Brooke E Harcourt; Melinda T Coughlan; Josepha Pete; Katarzyna Bialkowski; Adeline Tan; Angelika Bierhaus; Mark E Cooper; Josephine M Forbes
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-05-13       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.